ArticleBMC complementary medicine and therapies2026
Royal jelly protein hydrolysates accelerate in vitro diabetic wound healing by enhancing keratinocytes functions and suppressing macrophage-mediated inflammation.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe pathophysiology of diabetic wounds is underpinned by a vicious cycle of persistent inflammation and impaired re-epithelialization, posing a substantial challenge to clinical management. Therapeutic strategies capable of simultaneously targeting these interconnected pathologies are urgently needed. Royal jelly from Castanea mollissima Bl. (CmRJ) has previously demonstrated wound healing properties, yet the activity of its protein hydrolysates against diabetic complications has not been reported. This study focused on investigating the effects and mechanisms of the protein hydrolysates from CmRJ (CmRJPH) on the in vitro diabetic wounds, particularly on the functions of keratinocyte and macrophages.
methodsCmRJPH were trypsinized and then analyzed using MALDI-TOF MS and RPLC-MS/MS. The biological activities and the relevant mode of action of CmRJPH were assessed on the advanced glycation end products (AGEs)-damaged human keratinocytes (HaCaT) and lipopolysaccharide (LPS)-activated macrophages (Raw 264.7).
resultsCmRJPH was found to not only enhance the proliferation and migration of keratinocytes, but significantly rescue the impaired migratory function of an in vitro diabetic wound model induced by AGEs. Concurrently, CmRJPH exerted potent anti-inflammatory effects on LPS activated macrophages. It markedly suppressed the activation of the NF-κB signaling pathway, thereby curtailing the expression of the downstream pro-inflammatory effectors, including INOS, COX-2, IL-6, and TNF-α. Besides, CmRJPH exhibited strong antioxidant properties by scavenging DPPH and hydroxyl free radicals and reducing intracellular ROS levels in macrophages.
conclusionsThese findings suggested that CmRJPH had the potential to promote the healing of diabetic wounds by restoring the migratory capacity of impaired epithelial cells and concurrently resolving pathological inflammation. It offers new insights into the molecular mechanisms of RJ in promoting wound healing, positioning CmRJPH as a promising therapeutic candidate for the treatment of intractable diabetic wounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.